目的總結(jié)microRNA（miRNA）與乳腺癌浸潤(rùn)、轉(zhuǎn)移關(guān)系的研究進(jìn)展。 方法檢索并篩選近年來(lái)國(guó)內(nèi)外發(fā)表的有關(guān)miRNA與乳腺癌浸潤(rùn)、轉(zhuǎn)移關(guān)系的文獻(xiàn)并對(duì)其進(jìn)行綜述。 結(jié)果許多miRNA在乳腺癌發(fā)生、發(fā)展與浸潤(rùn)、轉(zhuǎn)移過(guò)程中都起著關(guān)鍵作用，按其作用可分為促癌miRNA（miR-21、miR-10b等）和抑癌miRNA（miR-31、let-7等）兩類。 結(jié)論miRNA調(diào)控乳腺癌浸潤(rùn)及轉(zhuǎn)移的具體過(guò)程還需要更多、更詳細(xì)的實(shí)驗(yàn)研究。
功能性單心室患者Fontan手術(shù)成功的關(guān)鍵主要取決于肺血管阻力。Fontan循環(huán)中高肺血管阻力將帶來(lái)各種并發(fā)癥，如運(yùn)動(dòng)耐量下降、低心排血量、心室功能衰竭和蛋白丟失性腸病，最終導(dǎo)致Fontan循環(huán)衰竭。因此，降低肺血管阻力的肺血管靶向藥物治療已成為學(xué)者近年的研究熱點(diǎn)。本綜述主要分析了靶向藥物波生坦和西地那非在肺動(dòng)脈壓和肺血管阻力增高的Fontan患者圍術(shù)期中的有效性和安全性。
人類免疫缺陷病毒（human immunodeficiency virus，HIV）感染主要攻擊人類免疫系統(tǒng)，引起各種機(jī)會(huì)性感染和腫瘤的發(fā)生，其中合并腫瘤性疾病嚴(yán)重且危及患者生命。近年來(lái)，隨著高效抗反轉(zhuǎn)錄病毒的普及，HIV感染者疾病譜發(fā)生了很大變化，非獲得性免疫缺陷綜合征（acquired immune deficiency syndrome，AIDS）相關(guān)腫瘤的發(fā)病率明顯升高，食管癌合并HIV/AIDS患者的診出率也隨之升高。然而，目前對(duì)于食管癌合并HIV/AIDS的患者如何規(guī)范化診斷與治療，尚未達(dá)成共識(shí)。本文將對(duì)食管癌合并HIV/AIDS患者的流行病學(xué)特征及診治進(jìn)展進(jìn)行綜述。
高效抗逆轉(zhuǎn)錄病毒治療（HAART）能重建機(jī)體對(duì)巨細(xì)胞病毒（CMV）在內(nèi)的許多病原的免疫反應(yīng)，不僅可以減少包括CMV視網(wǎng)膜炎在內(nèi)的CMV感染性疾病的危險(xiǎn)，還可以延長(zhǎng)獲得性免疫缺陷綜合征患者的生存期，提高生存率。但有必要加強(qiáng)HAART期間患者的免疫重建炎癥綜合征的監(jiān)護(hù)。
【摘要】 目的 探討重組人凝血因子Ⅷ制劑小劑量短程預(yù)防性輸注能否有效減少中重度血友病A患兒關(guān)節(jié)出血問(wèn)題。 方法 對(duì)2008年11月-2009年4月期間就診的13例年齡3~11歲的中重度血友病A患兒，均在為期2個(gè)月內(nèi)接受重組人凝血因子Ⅷ 2次/周、間隔3 d、每次7.5~10.0 U/kg的靜脈預(yù)防性輸注，記錄治療前2個(gè)月與治療2個(gè)月時(shí)關(guān)節(jié)出血次數(shù)，以及同一關(guān)節(jié)反復(fù)發(fā)生出血的情況。 結(jié)果 治療前關(guān)節(jié)出血的發(fā)生次數(shù)為（3.77±2.13）次，治療后關(guān)節(jié)出血的發(fā)生次數(shù)為（0.46±0.87）次，治療前后比較，差異有統(tǒng)計(jì)學(xué)意義（Plt;0.01）；治療前靶關(guān)節(jié)出血的發(fā)生率為35.7％，治療后靶關(guān)節(jié)出血的發(fā)生率為0.0%，治療前后比較，差異有統(tǒng)計(jì)學(xué)意義（Plt;0.01）。患兒治療成本約510~680元/（kg?2個(gè)月）?！〗Y(jié)論 重組人凝血因子Ⅷ制劑小劑量短療程預(yù)防性輸注能有效減少中重度血友病A患兒關(guān)節(jié)出血次數(shù)，同時(shí)可有效減少靶關(guān)節(jié)出血的發(fā)生率，從而在一定程度上保護(hù)關(guān)節(jié)的功能。治療費(fèi)用相對(duì)可接受?！続bstract】 Objective To evaluate the efficacy of low-dose short-course infusion of recombinant human factor Ⅷ concentration in treating joint bleeding in children with severe and moderate hemophilia A. Methods Thirteen children aged 3 to 11 years old with severe or moderate hemophilia A were included in the present study from November 2008 to April 2009. For children in the treatment group, they were treated with low-dose short-course infusion of recombinant human factor Ⅷ concentration with a dose of 7.5-10.0 U/kg twice weekly as secondary prophylaxis for two months. The incidence of joint bleeding 2 months before treatment (control group) and during the 2 months of treatment (treatment group) was observed. Moreover, the incidence of their target joint bleeding was measured in both groups. Results Children in the control group had (3.77±2.13) joint bleedings while children in the treatment group had (0.46±0.87) joint bleedings, which was obviously lower than those in the control group (Plt;0.01). Meanwhile, the incidence of target joint bleeding in the treatment group was 0%, which was obviously lower than that in the control group (35.7%) (Plt;0.01). In the treatment group, the costs of treatment were about RMB 510-680 yuan/kg every 2 months. Conclusions Treatment with low-dose short-course infusion of recombinant human factor Ⅷ concentration can effectively decrease joint bleeding in children with severe and moderate hemophilia A, and can effectively decrease the incidence of target joint bleeding. Therefore, this method may play an important role in protection of the joint function in those patients at an acceptable cost.
2007年1月-2009年12月，我們?cè)u(píng)價(jià)了彩色超聲心動(dòng)圖在肥厚型梗阻性心肌病化學(xué)消融術(shù)中的應(yīng)用價(jià)值，報(bào)告如下。